The Effect of MK0633 in Patients With Chronic Asthma (0633-007)

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of MK0633 in Adult Patients With Chronic Asthma

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00404313

Enrollment

688

Registered

2006-11-28

Start date

2008-01-31

Completion date

2009-06-30

Last updated

2015-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

A clinical study to evaluate the efficacy and safety of MK0633 in adult patients with chronic asthma.

Interventions

DRUGMK0633

Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633

DRUGComparator: placebo

Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Documented clinical history of symptoms of chronic asthma, including dyspnea, wheezing, chest tightness, cough, and/or sputum production * Males and females 18-70 years of age

Exclusion criteria

* History of kidney or chronic liver disease * Recent history of heart problems within the past 3 months * Evidence of another clinically significant, active lung disorder such as bronchiectasis or COPD

Design outcomes

Primary

Measure	Time frame
Pulmonary function test data measured over 6 weeks	6 weeks

Secondary

Measure	Time frame
Overall daytime and nighttime symptoms score, beta-agonist use, asthma exacerbations, asthma-specific quality of life questionnaire score, measured over 6 weeks	6 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026